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Abstract
Alzheimer’s disease (AD) is known as one of the major causes of dementia and is characterized by slow pro-
gression over several years, with no treatments or available medicines. In this regard, there have been efforts
to identify the risk of developing AD in its earliest time. While many of the previous works considered cross-
sectional analysis, more recent studies have focused on the diagnosis and prognosis of AD with longitudinal
or time series data in a way of disease progression modeling (DPM). Under the same problem settings, in
this work, we propose a novel computational framework that forecasts the phenotypic measurements of MRI
biomarkers and predicts the clinical statuses at multiple future time points. However, in handling time series
data, it generally faces with many unexpected missing observations. In regard to such an unfavorable situa-
tion, we define a secondary problem of estimating those missing values and tackle it in a systematic way by
taking account of temporal and multivariate relations inherent in time series data. Concretely, we propose a
deep recurrent network that jointly tackles the three problems of (i) missing value imputation, (ii) phenotypic
measurements forecasting, and (iii) clinical status prediction of a subject based on his/her longitudinal imag-
ing biomarkers. Notably, the learnable model parameters of our network are trained in an end-to-end manner
with our circumspectly defined loss function. In our experiments over The Alzheimer’s Disease Prediction
Of Longitudinal Evolution (TADPOLE) challenge cohort, we measured performance for various metrics and
compared our method to competing methods in the literature. Exhaustive analyses and ablation studies were
also conducted to better confirm the effectiveness of our method.
Keywords: Disease Progression Modeling, Alzheimer’s Disease, Deep Learning, Recurrent Neural
Networks, Missing Value Imputation, Longitudinal Data, Mild Cognitive Impairment, Conversion-Time
Prediction
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1. Introduction
Alzheimer’s disease (AD) is a catastrophic and progressive neurodegenerative disease that is clinically
characterized by the impairment of cognitive and functional abilities along with behavioral symptoms. It is
known that AD is the most common cause of dementia, accounting for about 70% of age-related demen-
tia (Alzheimer’s Association, 2019). It is estimated that there are approximately 50 million AD patients
around the world, and the figure will double by 2030 (Patterson, 2018), thus causing great social and eco-
nomic burdens (Brookmeyer et al., 2007; Alzheimer’s Association, 2019). Unfortunately, there is currently
no pharmaceutical or clinical treatment available to reverse or cure the progression of AD (Marinescu et al.,
2018; Gaugler et al., 2019). When considering the characteristics of patients with AD, the clinical symptoms
that disturb the activities of daily living, such as memory loss, language impediment, and other malfunctions,
become apparent only after several years from the time that the brain is initially affected by the disease (Braak
and Braak, 1996; Morris et al., 1996). For this reason, it is of great importance to identify the emergence of
the disease at its earliest stage or predict the risk of emergence as early as possible.
In recent decades, leveraging the advances in machine learning, especially deep learning, there have
been efforts to formulate the task of neuroimaging-based early AD diagnosis or prognosis as regression and
classification problems (Zhang et al., 2011; Suk et al., 2014, 2016; Liu et al., 2018b). On the one hand, many
of the existing studies focused on cross-sectional data analysis for AD diagnosis (Suk and Shen, 2013; Cheng
et al., 2017; Liu et al., 2018a). These studies showed reasonable performance in the clinical status prediction
task, even though only baseline features were used. However, they have limitations that did not properly
model the progressive deterioration of the disease and different occurrence time for each individual, which
are characteristics of AD.
On the other hand, in order to better utilize the available historical data, i.e., longitudinal data, disease
progression modeling (DPM) has drawn researchers’ attention (Sukkar et al., 2012; Peterson et al., 2017; Lee
et al., 2019; Lorenzi et al., 2019), especially for prediction of the time-to-conversion to the next clinical status
in the AD spectrum. The AD progression generally involves not only the acceleration of regional volume
atrophy (e.g., the hippocampus, which is presumed to show the earliest morphological changes due to AD)
but also increased enlargement of the ventricle over time (Nestor et al., 2008). These types of changes can be
better captured from longitudinal data, which allows for learning the underlying temporal characteristics in
the disease. Thus, with DPM, it may be possible to forecast the future changes in phenotypic measurements
and predict the time of conversion in clinical statuses that are symptomatically categorized as cognitively
normal (CN), mild cognitive impairment (MCI), and dementia (Mills and Tamnes, 2014). In particular, a
better understanding of the individual disease progression contributes to more accurate diagnosis, monitor-
ing, and prognosis, which are respectively beneficial for early diagnosis, intervention, and personalized care
(Oxtoby and Alexander, 2017). In this work, we focus on neuroimaging-based DPM for AD prognosis and
time-to-conversion prediction in the AD spectrum.
For the DPM, conversion time prediction is critical, as it gives us meaningful information about the dis-
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ease progression and the severity of the disease. It is much more challenging than just predicting whether
the patient will progress to AD. Conversion time prediction in this study is analogous to survival analy-
sis (Miller Jr, 2011; Oulhaj et al., 2009; Thung et al., 2018). Survival analysis is the study of time-to-event
data, modeling the expected period until event occurrence (e.g., disease status conversion) at a future time.
Although conversion time prediction resembles survival analysis, they actually tackle different approaches.
First, survival analysis focuses on predicting the probability of AD conversion at different future time points.
However, conversion time prediction forecasts when the conversion of the disease will occur. For example, in
general, probability methods (e.g., Cox regression model) are used to access the survival problems, while con-
version time prediction is based on typical regression methods (e.g., least-squares regression model) (Thung
et al., 2018). Our work investigates both problems.
In the literature on survival analysis and related fields, DPM has been widely applied when the causes of
diseases were not well-known or various factors were involved. Although working with longitudinal data is
useful for improving our knowledge of the disease, adding a temporal dimension entails different forms of
difficulties in data analysis, such as increasing dimensionality, missing values, and time alignment problems
(Ibrahim and Molenberghs, 2009). In a longitudinal dataset, there could be samples of subjects with one or
two follow-ups (‘short-term’) and those of subjects with a large number of follow-ups (‘long-term’) after
the first visit. With short-term data, we might not suffer from missing measurements and data imbalance
problems, but we are restricted from learning patterns of long-range dependence by nature, thus limited in
building a reliable model for DPM (Ardekani et al., 2017; Fiot et al., 2014; Gray et al., 2012; Shi et al.,
2017). Meanwhile, long-term longitudinal data are potentially better suited for DPM by allowing us to get
better insights into the global patterns in disease progression (Bilgel et al., 2015; Guerrero et al., 2016; Bilgel
et al., 2016; Aghili et al., 2018), but generally have issues of many missing measurements and time alignment,
due to research or patients drop out or unexpected accidents, etc. (Petersen et al., 2010).
Some studies (Wei et al., 2016; Zhang et al., 2012; Misra et al., 2009) have been developed for MCI-to-
AD conversion, which represents who will progress to AD. (Wei et al., 2016) used MRI thickness measures
as features to predict MCI-to-AD conversion. They used data at the baseline and up to 18 months (short-term
samples). Meanwhile, (Misra et al., 2009) used longitudinal MRI data to extract the changes of brain atrophy
for detecting MCI-to-AD conversion. However, this study employed a short period follow-up data (up to 15
months). In addition, Zhang et al. also utilized longitudinal MRI data up to 24 months to predict clinical
scores as well as the conversion of MCI patients by longitudinal feature selection method that extracts the
brain regions across multiple time points (Zhang et al., 2012).
More recently, we have witnessed the potential of deep learning methods (Wang et al., 2018; Lee et al.,
2019; Ghazi et al., 2019; Jung et al., 2019) for DPM thanks to their favorable characteristics of learning
feature representations from data, rather than engineering feature manually. Especially, recurrent neural net-
works (RNNs) and their variants have been mostly employed because of their methodological ability to handle
the time alignment issue among intra- and inter-subject trajectories. In particular, long short-term memory
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(LSTM) (Hochreiter and Schmidhuber, 1997) is one of the successful techniques to encode temporal patterns
(Wang et al., 2018; Yoon et al., 2018; Ghazi et al., 2019; Jung et al., 2019) by capturing long-term depen-
dencies among multivariate measurements over time with efficient gating-based operations (Gers et al., 1999;
Gers and Schmidhuber, 2001). However, its use in DPM remains challenging with incomplete samples, i.e.,
missing measurements in the data. For that reason, the previous works (Lipton et al., 2016; Wang et al., 2018;
Ghazi et al., 2019; Yoon et al., 2018) have mostly involved the step of missing value imputation either as a
means of preprocessing prior to training RNNs (Lipton et al., 2016; Wang et al., 2018) or by regarding it as a
sub-task of the target model training for prediction (Yoon et al., 2018).
For example, Lipton et al. exploited RNNs with LSTM cells to diagnose the pediatric intensive care unit
(PICU) from clinical time series data (Lipton et al., 2016). Wang et al. also used them to predict future clinical
scores given 11 yearly observations (Wang et al., 2018). When training their method, all missing values of the
patients’ historical observations due to varying number of visits and uneven time intervals, were first imputed
by simple mean or forward imputation methods (Lipton et al., 2016; Wang et al., 2018), disregarding both
the temporal relations and multivariate relations of observations. Ghazi et al. formulated the task of AD
progression modeling by means of predicting changes in volumetric MRI biomarkers in a vanilla LSTM with
peephole connections (Gers and Schmidhuber, 2000) added to all the gates (Ghazi et al., 2019). In their work,
when training their model, all the missing values of longitudinal samples were initialized with zeros, and no
further imputation update was conducted. Here, we named this model as PLSTM-Z. It is also noteworthy that
for the clinical status prognosis, they built a separate classifier with linear discriminant analysis (LDA) by
taking the predicted biomarker values from the trained PLSTM-Z as input features.
Since the performance of predictive models with preprocessing-based missing value imputation are highly
dependent on the static values, e.g., zeros and means, determined manually or statistically, some researchers
have devoted their efforts to constructing adaptive and dynamic imputation models. For example, Yoon et
al. focused on the task of missing value imputation and utilized a bi-directional RNN to better take into ac-
count temporal relations, but no relations among multivariate features, for mortality prediction with electronic
health records (Yoon et al., 2018). More recently, Cao et al. gave special attention to the task of missing val-
ues imputation in time series data (Cao et al., 2018). In particular, given a sequence of observations in a fixed
time interval, they designed the LSTM model, the one in the original time order and the other in the reversed
time order, to maximally utilize the inherent temporal relations along with multivariate relations. However,
due to the use of a time-reversed sequence, their imputation method is not applicable for disease progression
modeling, which is what we care about for long-term prognosis.
Inspired by the recent work of dynamic imputation methods described above, in this work, we hypothesize
that both multivariate and temporal relations inherent in longitudinal data could be informative to estimate
missing values. It is also believed that the appropriately imputed values help enhance the predictive power of
a model for downstream tasks, i.e., in our work, volumetric MRI biomarker changes and clinical status prog-
nosis over multiple time points ahead, thus making it possible to infer time-to-conversion in the AD spectrum.
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In these regards, we propose a unified framework that can (i) adaptively impute missing values (‘imputation
module’), (ii) encode imputed observations into latent representations via LSTM (‘encoding module’), and
(iii) predict both future MRI volumetric measurements and clinical statuses (‘prediction module’) over time
in terms of the AD progression from a subject’s historical measurements. Methodologically, we devise an
imputation architecture that takes advantage of the encoded latent representations from an LSTM cell, i.e.,
temporal relations, and utilizes multivariate relations among variables to infer missing values. For the tem-
poral encoding in LSTM-Z (LSTM with zero imputation), we feed the complete observation, i.e., replace the
missing values with imputed ones, a mask vector that indicates which values are imputed, and the informa-
tion of time-delay from the last observed times. These all together greatly help to better encode and capture
temporal characteristics in a longitudinal sample for modeling disease progression. Further, we also design
an objective function such that the network parameters of all the three modules can be trained jointly in an
end-to-end manner.
We evaluated the performance of our proposed method using the longitudinal cohorts from ‘The Alzheimer’s
Disease Prediction Of Longitudinal Evolution (TADPOLE)’ Challenge2 in terms of (i) future volumetric
biomarker regression and (ii) clinical status classification, respectively. Furthermore, we conducted exhaus-
tive analyses to verify the effectiveness of the proposed framework for AD progression in three aspects,
namely, model perspective analysis, longitudinal stability analysis, and personalized analysis.
The main contributions of our work can be summarized as follows:
• To the best of our knowledge, our work is the first to use a novel deep recurrent network that jointly
performs missing value imputation, future MRI biomarker forecasting, and clinical status prognosis
over multiple time points in a unified framework.
• A multi-objective function for the proposed imputation-encoding-prediction network is devised and
optimized in an end-to-end manner.
• Compared to the competing methods considered in our experiments, our proposed method outper-
formed them in all metrics for imputation, regression, and classification.
This work extends the preliminary version published by (Jung et al., 2019) by revising the network archi-
tecture and performing more rigorous experiments and analyses.
2. Materials and Preprocessing
In this work, we used the TADPOLE longitudinal cohort3 from the ADNI database, including ADNI-1,
ADNI-2, and ADNI-GO. The main objective of the challenge was to track the progression of subjects with
AD using MRI biomarkers and clinical measurements. The dataset includes 1, 500 kinds of longitudinal MRI
2https://tadpole.grand-challenge.org/
3Available at ‘https://tadpole.grand-challenge.org/Data/’
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Figure 1: An example of morphological changes of six regions in a subject’s brain. The color-coded values indicate the amount of volume
changes from a baseline time point. The darker color of either blue or red, the more shrunk or enlarged volume from a baseline time
point.
biomarkers, e.g., cortical thickness and cortical volume, from 1, 737 patients (aged from 54.40 up to 91.40)
with 12, 741 visits at 22 different time points between 2003 and 2017 (Marinescu et al., 2018). The summary
of the TADPOLE dataset is presented in Table A.1.
As our main objective in this work is to predict the yearly progression, we considered 11 regular visits
out of 22 total visits. In the TADPOLE dataset, the clinical groups were labeled as 342 AD, 417 CN, 310
EMCI (early MCI), 562 LMCI (late MCI), and 106 SMC (significant memory concern). Like the previous
work (Ghazi et al., 2019; Jung et al., 2019), we merged the groups of CN and SMC into CN, and EMCI
and LMCI into MCI, thus resulting in three categories: CN, MCI, and AD. Moreover, from the original
TADPOLE dataset, we excluded subjects with no visit on the baseline or having less than 3 visits, resulting
in a total of 773 subjects in the end. The number of longitudinal measurements ranges from 4 to 11 with
5.76(mean) ± 2.07(std). The duration of sequences ranges from 36 to 120 with 61.54(mean) ± 27.21(std).
The detailed information of demographic and clinical scores for samples used in our work is summarized in
Table C.2 over 11 yearly time points. Note that there are many missing observations in the MRI biomarkers
and clinical labels over the selected dataset.
Although the TADPOLE dataset offers numerous kinds of biomarkers to forecast the AD status (Mari-
nescu et al., 2018), by following (Ghazi et al., 2019) in this paper, we considered the six volumes of ventricles,
hippocampus, fusiform gyrus, middle temporal gyrus, entorhinal cortex, and whole-brain, extracted from the
T1-weighted MRI that are shown in Fig. B.1. We normalized the original values of the biomarkers with
each subject’s intracranial volume (ICV) to compensate for the inter-subject variability in brain size (Davis
and Wright, 1977; Ghazi et al., 2019) and further conducted feature-wise linear normalization based on the
min/max values to be in the range of [−1, 1]. For a reference, we illustrated an example of morphological
changes of six regions in a subject’s brain, who experienced three clinical statuses during the 11-year period,
in Fig. 1.
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(a) A proposed deep recurrent network architecture
(b) An architecture of our imputation module (c) An architecture of our encoding module
Figure 2: (a) The architecture of the proposed method combines three modules, i.e., imputation, encoding, and prediction. The modules
impute the missing values of the current input, forecast the biomarker values, and predict the clinical status at the next time sequence. (b)
Operations to consider the feature-based relations and temporal relations in estimating missing values. (c) A variant of a vanilla LSTM
unit with γ andmx,t. For simplicity, the biases are excluded. If unobserved, the predicted values are used as the input of the next time
step, which is denoted as dotted arrows. Solid arrows indicate the process of architecture.
3. Proposed Method
In this work, we propose a novel framework for AD progression modeling with incomplete longitudinal
data. Specifically, our proposed method is composed of three modules, namely, an imputation module, encod-
ing module, and prediction module, as illustrated in Fig. 2a. At a certain time point, the imputation module
first estimates missing values using the encoded latent representations from the previous time point in a deep
recurrent network, as well as the multivariate relations among the observed values of the current time point.
Second, the encoding module receives the complete observation with the missing values replaced by imputed
ones, a mask vector that indicates which values are imputed, and the information of time-delay from the last
observed time points. They encode and capture temporal characteristics in the given longitudinal data. Lastly,
the encoded representations are transformed to forecast the volumetric measurements and predict the clinical
status of the next time point.
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3.1. Notations
Throughout the paper, we denote matrices as boldface uppercase letters, vectors as boldface lowercase
letters, and scalars as normal italic letters. For a matrix A, its (i, j)-th element and the i-th column are denoted
as A(i, j) and ai, respectively. For a vector a, its i-th element is denoted as a(i).
Assume that a set of multivariate time series of D variables over T times from N number of subjects are
given
{
X(n),Y(n)
}N
n=1
, where X(n) =
[
x
(n)
1 , . . . ,x
(n)
t , . . . ,x
(n)
T
]
∈ RD×T , Y(n) =
[
y
(n)
1 , . . . ,y
(n)
t , . . . ,y
(n)
T
]
∈
{0, 1}K×T , and K denotes the number of classes considered in a target task. In our case, it corresponds to
the clinical state of a patient, i.e., CN, MCI, and AD. To limit clutter, hereafter we omit the superscript (n)
unless it is unclear in the context.
To better use the temporal information regarding both missing value imputation and latent feature rep-
resentation, we will consider a time delay for each observation from the last observation time. For this, we
define an auxiliary variable s ∈ RT that indicates when the observations were acquired, and a time delay
matrix ∆ ∈ RD×T , whose elements i.e., ∆(d, t) or δt, are set as follows:
∆(d, t) =

s(t)− s(t− 1) + ∆(d, t− 1) if t > 1,Mx(d, t− 1) = 0,
s(t)− s(t− 1) if t > 1,Mx(d, t− 1) = 1,
1 if t = 1.
3.2. Missing Values Imputation
We design an architecture that jointly exploits temporal and multivariate relations for imputation. Our
imputation module is based on a deep recurrent neural network, which becomes an encoding module as
described in Section 3.3. Specifically, we take the hidden state values of a recurrent network for the context
of temporal relations in a given sequence.
At time t, the previous temporal context information up to (t− 1) is encoded in the hidden state ht−1 of
an encoding module. From the hidden state ht−1, we first use the temporal relations for the estimation of the
MRI measurements of the current time t as follows:
xˆt = Wxht−1 + bx (1)
where Wx and bx are learnable parameters. Then, by exploiting the masking vector mx,t, we obtain a
temporary vector xct by replacing the missing values with those estimated from the temporal relations, while
maintaining the observed MR features as follows:
xct = mx,t  xt + (1−mx,t) xˆt. (2)
We also consider multivariate relations among the MRI features of the imputed temporal vector xct in Eq.
(2) by introducing learnable parameters Wz and bz as follows:
zˆt = Wzx
c
t + bz. (3)
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Here, it should be noted that we constrain the diagonal elements in Wz to be zero, such that the values
of elements in zˆt are obtained from those of the other variables in xct only, thereby focusing purely on the
multivariate relations.
Using temporal and multivariate relations, two imputed vectors, xct and zˆt, are obtained as described
above. Now, for robustness, we further consider combining these two vectors by introducing a weighting co-
efficient vector that is dynamically determined, based on the missing patterns. Regarding the missing patterns,
there are two sources of information, the masking vector mx,t and the time delay from the last observation
in δt. We use the time delay information by defining a time decay factor γt ∈ (0, 1]D as follows:
γt = exp{−max(0,Wγδt + bγ)} (4)
where Wγ and bγ are tunable parameters. Combining this time decay factor with a masking vector via
concatenation, we compute the weighting coefficient vector βt as follows:
βt = σ(Wβ · [γt ⊕mx,t] + bβ) (5)
where σ denotes a logistic sigmoid function to guarantee that the coefficients are in the range of (0, 1).
Thus, βt carries the integrated information about the time decay factors γt and the missing patterns at the
current time step. With this weighting coefficient vector βt, we finally estimate the missing values using an
interpolation between xˆt and zˆt
uˆt = βt  zˆt + (1− βt) xˆt. (6)
Consequently, we obtain the ‘complete’ observation vector uct by replacing the missing values with the esti-
mates in Eq. (6)
uct = mx,t  xt + (1−mx,t) uˆt. (7)
3.3. Recurrent Temporal Encoding and Multi-task Prediction
After imputing the missing values, we exploit deep recurrent network for temporal encoding. Here, to
better reflect the existence of missing values in an observation, we devise a novel computational mechanism,
i.e., a variant of a vanilla LSTM cell with γ and mx,t. In other words, the complete value uct in Eq. (7) is fed
into the recurrent model.
First, as in the imputation module, we use the time delay information in δt, which is one of the important
sources for temporal patterns (Che et al., 2018). That is, although the temporal context information up to
the previous time (t − 1) is represented in the hidden state ht−1 of a recurrent network, their influence in
encoding with the current observation uct should be treated in different ways depending on when the ‘real’
last observation was acquired. Therefore, we use this crucial information with a temporal decaying factor γt
in Eq. (4) before embedding with the current observation uct as follows:
hˆt−1 = ht−1  γt. (8)
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Meanwhile, we also feed the masking vector mx,t to the encoding module to let it know which values are
the imputed ones estimated from our imputation module. Concretely, the internal operations in our encoding
module are as follows:
ft = σ
(
Wf · [hˆt−1,uct ⊕mx,t] + bf
)
it = σ
(
Wi · [hˆt−1,uct ⊕mx,t] + bi
)
c˜t = tanh
(
Wc · [hˆt−1,uct ⊕mx,t] + bc
)
ct = ft · ct−1 + it · c˜t
ot = σ
(
Wo · [hˆt−1,uct ⊕mx,t] + bo
)
ht = ot · tanh (ct)
where {Wf ,Wi,Wc,Wo,bf ,bi,bc,bo} are the learnable parameters of our modified LSTM cell. ft, it, c˜t,
and ot represent the outputs of the forget, input, update, output gates, respectively.
Based on the hidden state representation ht from the encoding module, our prediction module produces
two outcomes, i.e., the MRI measurements x¯t+1 and the clinical state y¯t+1 of the next time point. We use
simple linear and logistic regression models for each of the outcomes as follows:
x¯t+1 = Wght + bg (9)
y¯t+1 = softmax(Wyht + by) (10)
where Wg,Wy,bg , and by are parameters. Thus, our prediction module is connected with the encoding
module, and the parameters can be tuned jointly with those of the encoding module. From a learning stand-
point, this prediction module takes the advantage of a multi-task learning strategy for more predictive rep-
resentations, comparable to the work of (Ghazi et al., 2019), where they first conducted MRI measurements
forecasting and then built an independent classifier for clinical status prediction. In Section 5.1, we present
the validity of our multi-task learning by comparing it with the counterpart single-task learning.
3.4. Learning
We defined a composite loss function for the joint training of the three modules, i.e., missing value impu-
tation, temporal encoding, and output prediction. Specifically, for the imputation loss Limputation, we measure
the similarity between the observed data and the imputed data by the mean absolute error (MAE) from three
different perspectives, i.e., temporal relations in Eq. (1), multivariate relations in Eq. (3), and composite rela-
tions in Eq. (6).
Limputation =
T∑
t=1
(|x˜t − xˆt|+ |x˜t − zˆt|+ |x˜t − uˆt|) (1− m˜x,t) (11)
where x˜t = xt mx,t and M˜x,t is a masking matrix of random removal from observations for imputation
module training only. Empirically, when comparing with a loss defined only with the final imputed values ucx
in Eq. (7), i.e., |x˜t − ucx|, the joint loss in Eq. (11) enhanced the stability and speed in training.
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As for the MRI biomarker prediction loss Lbiomarkers, we assessed the correspondence between the model
prediction x¯t+1 and the future real MRI measurements xt+1 as follows:
Lbiomarkers =
T−1∑
t=1
(xt+1 mx,t+1 − x¯t+1 mx,t+1)2 . (12)
Lastly, for the clinical prognosis, we exploited the focal cross-entropy loss Lprognosis (Lin et al., 2017) due to
the imbalance in samples among the class labels:
Lprognosis = −
T−1∑
t=1
my,t
[
K∑
k=1
yt(k)(1− y¯t(k)) log(y¯t(k))
]
(13)
where  is a hyperparameter ( ≥ 0). Therefore, we define the overall loss function Ltotal as follows:
Ltotal = αLimputation + ζLbiomarkers + ξLprognosis (14)
where α, ζ, and ξ are the hyperparameters to weight the corresponding losses. The optimization of this loss
function allows us to train all the parameters of the three modules, i.e., imputation, encoding, and prediction,
via stochastic gradient descent in an end-to-end manner.
4. Experimental Results and Analysis
4.1. Experimental Settings
We validated the effectiveness of the proposed framework that systematically unifies data-driven missing
value imputation and multi-task learning for AD progression modeling in tasks of missing value imputation
at the current time and MRI biomarker forecasting and clinical status prediction, we made predictions for
every time point (with a one-year interval between consecutive time points) up to 11 time points, thus the
next 10 years from the baseline. For each time point, the prediction was conducted based on all the observed
historical values and the predicted or imputed values, if unobserved or missing.
We reported the average test results from 5-fold cross-validation. Specifically, we partitioned the dataset
described in Section 2 into three non-duplicated subsets for training, validation, and testing. For rigorous
evaluation, we randomly selected 10% of the subjects in each class as the validation set and another 10% as
the test set from the baseline time point. For the imputation task, we randomly removed 10% of the ‘true’
observation values in samples from all train, validation, and test sets and then used them as the ground truth.
However, we utilized all true observation values for the prediction tasks. For quantitative evaluation, we used
the metrics of MAE and mean relative error (MRE) for the imputation task, MAE for the MRI biomarker
prediction task, and multi-class area under the receiver operating characteristic curve (mAUC) (Hand and
Till, 2001) for the clinical status prediction task. We also conducted statistical significance tests in comparison
with the competing methods. Briefly, we used the paired, two-sided Wilcoxon signed-rank test (Wilcoxon,
1992) for regression tasks, i.e., imputation and MRI biomarkers forecast, on MAE and MRE. Meanwhile,
McNemar’s test (McNemar, 1947) on mAUC was applied for the clinical status prediction task.
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Table 1: Performance for an imputation task in terms of MAE and MRE (mean±std). The best performance is indicated in boldface.
Models MAE MRE
LSTM-M (Wang et al., 2018) 0.076± 0.014† 0.260± 0.063†
LSTM-F (Lipton et al., 2016) 0.073±0.012† 0.246± 0.045†
MRNN (Yoon et al., 2018) 0.145± 0.022∗ 0.485± 0.102∗
PLSTM-Z (Ghazi et al., 2019) 0.107± 0.013∗ 0.376± 0.052∗
Ours 0.073±0.009 0.239±0.056
(∗ : p < 0.05, † : no statistical difference)
We compared our proposed method with the following methods that deal with missing values imputation
and prediction tasks:
• Mean imputation with LSTM (LSTM-M) (Wang et al., 2018): Missing values were imputed with the
mean values of the respective variables in a training set, and a standard LSTM network was used for
temporal encoding and MRI biomarker prediction, which was then used for classification with LDA.
• Forward imputation with LSTM (LSTM-F) (Lipton et al., 2016): This is the same as the LSTM-M,
except that the missing values were imputed with the most recent observed values.
• Zero imputation with Peephole LSTM (PLSTM-Z) (Ghazi et al., 2019): A peephole LSTM (Gers and
Schmidhuber, 2000) was used for MRI biomarker prediction with missing values imputed by zeros as
input. The predicted MRI biomarkers were then used for classification via LDA.
• Multi-directional RNN (MRNN) (Yoon et al., 2018): This operates forward and backward within the
intra-stream directions, i.e., for each variable, and in the inter-stream directions, i.e., among variables.
Unlike a typical bidirectional-RNN, the timing of inputs into the hidden layers was lagged in the for-
ward direction and advanced in the backward direction. The network outputted the MRI biomarker
measures for the next time point, which were then fed into LDA for clinical status prediction.
For all the competing methods, we set 64 hidden units and trained them using an Adam optimizer (Kingma
and Ba, 2014) with a learning rate of 5 × 10−3, a mini-batch size of 64, and an epoch of 300. To avoid an
overfitting problem and make the training curve converge considerably, we applied an `2-regularization by
setting the corresponding coefficient to 10−4. Regarding the hyperparameters of the composite loss function
in Eq. (14), we set them as α = 1.0, ζ = 1.0, and ξ = 0.75. In Eq. (13), we set  = 4. For evaluation on the
test set, we chose the optimal parameters of the comparative networks that achieved the highest mAUC over
the validation set.
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Table 2: Performance of forecasting MRI biomarkers one-year later in terms of MAE (mean±std). The smallest MAE for each MRI
biomarker is highlighted in boldface.
Models
MAE (×10−3)
Ventricles Hippocampus Whole Brain Entorhinal Cortex Fusiform Gyrus Middle Temporal Gyrus
LSTM-M
8.47±1.81
∗
0.40±0.05
∗
30.04±7.50
∗
0.30±0.05
∗
0.89±0.22
∗
0.97±0.19
∗
(Wang et al., 2018)
LSTM-F
8.93±2.50
∗
0.42±0.02
∗
28.96±7.36
∗
0.27±0.05
†
0.90±0.09
∗
0.97±0.17
∗
(Lipton et al., 2016)
MRNN
5.02±0.84
∗
0.33±0.03
∗
21.07±2.26
∗
0.26±0.02
∗
0.70±0.05
∗
0.80±0.07
∗
(Yoon et al., 2018)
PLSTM-Z
2.79±0.44
†
0.29±0.08
†
16.75±4.59
†
0.23±0.04
∗
0.56±0.08
†
0.64±0.09
†
(Ghazi et al., 2019)
Ours 2.21±1.42 0.18±0.04 11.82±2.31 0.19±0.02 0.42±0.08 0.51±0.09
(∗ : p < 0.05, † : no statistical difference)
4.2. Performances
4.2.1. Missing Value Imputation
We presented the experimental results of the missing values imputation in Table 1. First, it is notewor-
thy that our proposed method achieved the lowest MAE and MRE scores, outperforming all the competing
methods under our consideration with a statistical significance of p < 0.05 for MRNN and PLSTM-Z, but
not for LSTM-M and LSTM-F. Interestingly, LSTM-M and LSTM-F, which took the simple mean or the
last observed values for imputation, achieved relatively better performance than their counterpart method of
PLSTM-Z that imputed with zeros and applied a peephole LSTM. Further, as for the MRNN, even though
it used the multi-directional information of temporal and multivariate relations, it reported the highest MAE
and MRE scores. Although both our proposed method and MRNN utilized two kinds of information sources,
i.e., temporal relations and multivariate relations, our method further considered missing patterns in Mx and
time delay in ∆ systematically through a series of operations, as described in Section 3.2. We believe that
this systematic imputation significantly enhanced the performance. The related more rigorous ablation study
on the effectiveness of the time delay and missing pattern information is presented in Section 5.2.
4.2.2. MRI Biomarkers Forecast
The forecast errors in MAE over six MRI biomarkers are presented in Table 2. Unlike the imputation task,
LSTM-M and LSTM-F, which used simple imputation, and typical LSTM resulted in relatively higher errors
across the MRI biomarkers. Meanwhile, the use of temporal and multivariate relations for hidden state repre-
sentation in MRNN helped to boost performance compared to LSTM-M and LSTM-F. From those results, it
could be hypothesized that the MRI biomarker forecast was not necessarily helpful to the downstream task.
However, our understanding of this phenomenon is that because the amount of longitudinal changes of the
MRI biomarker values had been small, the simple static values were somehow close to the ground truth on
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Table 3: Performance on a multi-class (AD vs. MCI vs. CN) classification task (mean±std). The best performance in each metric is
highlighted in boldface.
Models mAUC Recall Precision
LSTM-M (Wang et al., 2018) 0.688±0.048∗∗∗ 0.607±0.209 0.492±0.077
LSTM-F (Lipton et al., 2016) 0.659±0.108∗∗∗ 0.475±0.193 0.480±0.060
MRNN (Yoon et al., 2018) 0.724±0.015∗ 0.635±0.166 0.489±0.086
PLSTM-Z (Ghazi et al., 2019) 0.712±0.007∗∗∗ 0.624±0.148 0.480±0.110
Ours 0.750±0.030 0.655±0.228 0.501±0.085
(∗ : p < 0.05, ∗∗ : p < 0.01, ∗ ∗ ∗ : p < 0.001, †: no statistical difference)
average, but it was not helpful for those simple static values to capture the temporal and multivariate relations
inherent in the data. As for PLSTM-Z, whose major difference from LSTM-M, LSTM-F, and MRNN was the
use of a peephole LSTM, it achieved much better MAE scores for all the biomarkers. However, our proposed
method4 was even superior to PLSTM-Z, with margins of 0.58 (ventricles), 0.11 (hippocampus), 4.93 (whole
brain), 0.04 (entorhinal cortex), 0.14 (fusiform gyrus), and 0.13 (middle temporal gyrus). From those results,
we argue that the piece of masking pattern information played a key roles, as discussed in Section 5.2.
4.2.3. Clinical Status Prediction
In the clinical status prediction task, due to high imbalance in sample sizes among the three classes of AD,
MCI, and CN, we also reported precision and recall, along with mAUC, in Table 3. Notably, like the MRI
biomarker forecast, LSTM-M and LSTM-F based on the standard LSTM architecture were inferior to the
other competing methods. Among the comparative methods, MRNN (Yoon et al., 2018) resulted in boosted
performance in all metrics of mAUC, recall, and precision. Meanwhile, our proposed method5 outperformed
all the competing methods by achieving the highest scores in mAUC, recall, and precision with margins of
0.026, 0.020, and 0.012, respectively, compared to MRNN.
5. Discussion
5.1. Effect of Multi-task Learning
It is noteworthy that in the clinical status prediction task, one of the major differences of our method
from the other comparative methods was to jointly optimize the parameters of the MRI biomarker forecast
regressor and the clinical status prediction classifier. Thus, we also conducted an experiment by modifying
our method such that it was trained with a single task of MRI biomarker prediction, and then independently
4The yearly detailed performance of our method is presented in Table D.3.
5The yearly computed performance of our method and the respective confusion matrices are presented in Table D.3 and Fig. D.2,
respectively.
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Figure 3: Result of ablation studies regarding the influence of a pair of hyper-parameters in the loss function {α, ζ, ξ} in the classification
task on the TADPOLE dataset.
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Figure 4: Result of ablation studies on the effectiveness of the time delay and missingness information for the proposed method. In this
case, we selected the classification results from the setting of the  value, which is the hyperparameter in the focal loss function.
trained an LDA-based classifier, under the same condition as the comparative models. That is, we trained our
model by setting the hyperparameters of ξ = 0 (α = 1.0, ζ = 1.0) in the composite loss function.
In single-task learning, the results of our method were 0.734± 0.015 in mAUC, 0.558± 0.159 in recall,
and 0.478 ± 0.114 in precision, respectively, which are still higher than the counterpart methods with a
margin of 0.046 (vs. LSTM-M), 0.075 (vs. LSTM-F), 0.010 (vs. MRNN), and 0.022 (vs. PLSTM-Z) in terms
of mAUC. When comparing between single-task and multi-task learning in our proposed method, the joint
learning of MRI biomarker forecast and clinical status prediction was helpful at enhancing the performance
by 0.016 in mAUC, 0.097 in recall, and 0.023 in precision.
5.2. Ablation Studies
As a part of the ablation study, we first investigated the effect of varying the pair {α, ζ, ξ} as the hyper-
parameters, which is introduced in Eq. (14). We considered these parameters as a ratio to weigh the missing
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values and future biomarker regression and clinical status classification to achieve optimal performance. For
each parameter, we defined a set of range values for these hyperparameters as {0.1, 0.25, 0.5, 0.75, 1.0}, illus-
trated in Fig. 3. Derived from the highest validation AUC, our proposed method reached the highest average
AUC score of 0.750 with α = 1.0, ζ = 1.0, and ξ = 0.75.
Unlike the comparative methods in our experiments, our proposed method used a focal loss that considers
the imbalance of samples among classes. Thus, we experimented by varying the value of the hyperparameter
 in Eq. (13) from 0 to 5 with an interval of 1. The result is presented in Fig. 4 with a blue solid line. Note that
when  = 0, which corresponds to the conventional cross-entropy loss, the mAUC was 0.732 ± 0.020 still
outperforming the competing methods. Clearly, due to the high imbalance in the number of samples in our
training set, it was useful in improving the performance to apply non-zero values for , recording the highest
when  = 4.
To justify the effect of using the missingness information, i.e., the use of mask vectors, and the time-
delay information between observed values, we also conducted experiments with and without those pieces
of information. The results are shown in Fig. 4. Although there were no consistent patterns in the effect of
delay and missingness information, it is worth mentioning that their joint use always achieved the highest
performance over different values of .
5.3. Prediction at Multiple Time Points within a 10-Year Range
To verify the validity of our proposed method for multiple-time-points prediction, we compared the prog-
nostic performance between MRNN, PLSTM-Z, and our method, which ranked in the top three in mAUCs
for single next-time-point prediction in Table 3. At each time point, we made clinical status predictions for
multiple subsequent time points up to 10 years beyond the baseline with the historical observations and the
imputed or predicted values for missing ones. To do this, we divided 10 cases based on the number of his-
torical time points used for clinical status prediction, and then measured the mAUC for each case. As an
example, for case 5, when having used 5 historical time points, from 0 (baseline) to 4 (4 years), then the
clinical statuses over the following 5 time points (5 years) were predicted, along with the MRI biomarker
forecast. The mAUC of those methods over time are presented with line graphs in Fig. 5. In the figure, we
also plotted our proposed method’s performance in one-time-point prediction with a dotted blue line for ref-
erence. First, from a bias-variance point of view, our proposed method notably showed high (i.e., low-bias)
and stable (i.e., low-variance) mAUC scores across the cases. Meanwhile, PLSTM-Z and MRNN showed
low mAUC (i.e., high-bias) and unstable mAUC (i.e., high-variance), respectively. Second, the data-driven
imputation methods of MRNN and ours were superior to the counterpart method of PLSTM-Z.
For the early identification of the risk for a subject who is possibly to progress to AD, we also considered
the predictive accuracy of our method in terms of conversion-to-AD within the period of consideration. Based
on our 10-year range prognosis, we measured the accuracy and MAE for the conversion-to-AD, and the results
are illustrated in Fig. 6. In the figure, we observed that the accuracies improved, and MAE decreased, across
the cases.
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Figure 5: Disease prognostic results from historical observations between the proposed method, MRNN, and PLSTM-Z. From top to
bottom, the panels display the disease prognostic performance over time using our method, MRNN, and PLSTM-Z. Specifically, the
colored lines in each panel mean that the patient’s disease prognosis results are represented using accumulated data up to that point. In
addition, we plotted the comparative method’s performance in one-time-point prediction with a dotted magenta line.
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Figure 6: Conversion-to-AD accuracy for our proposed method. Each box indicates the ability to capture changes in a patient’s disease
status. Furthermore, the solid line represents the absolute values of the difference between the actual patient label transition time and
the model’s predictive label conversion time. Note that each case denotes that conversion-to-AD predictions are performed using data
accumulated up to that time.
5.4. Irreversible Neurodegenerative Alzheimer’s Disease
The predictive models should also reflect such pathological characteristics as the irreversible neurodegen-
eration of AD. That is, if a subject is under the state of AD at one point, it is not expected for the subject
to reverse to MCI or CN in the future. With this consideration, we compared the longitudinal clinical status
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Figure 7: Results of longitudinal status prediction between the proposed method, MRNN, and PLSTM-Z. The plots in each panel repre-
sent clinical status conversion from different subjects. Green, yellow, and red represent CN, MCI, and AD in the true label, respectively.
predictions of MRNN, PLSTM-Z, and our proposed method, shown in Fig. 7. In the figure, we presented
predictions for five different subjects with different progression types. While MRNN and PLSTM-Z made
many state-reversing predictions, our proposed method did not show any such non-acceptable predictions.
For the subjects with CN (Fig. 7a) or MCI (Fig. 7c), our method predicted CN or MCI over the whole period.
In Fig. 7b, 7d, and 7e, although predictions are misplaced ahead or behind by one or two time points, our
method did not make any state-reversing predictions.
5.5. Interpreting Cell States
While our deep recurrent network achieved relatively superior performance in both MRI biomarker fore-
casting and clinical status prediction, it is desirable to understand the dynamics of the internal state represen-
tations of our proposed model. In this regard, we devised a novel analysis method of the cell states in our
LSTM. To determine which cell states contributed to the identification of the clinical statuses, we estimated
the correlation between a patient’s disease statuses over time and the corresponding cell state representations.
Specifically, we first collected the internal cell representations of ≈ 19 subjects (19.2 ± 5.0)6, who experi-
enced status-conversion during our period of interest, and then measured the correlations between the change
of the values in the cell states and a transition of the patient’s disease status (0: no conversion and 1: conver-
sion) with point-biserial correlation coefficients. We grouped all subjects depending on the disease transitions
6This value represented the mean and standard deviation over the number of subjects in 5-fold cross-validation.
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Figure 8: Normalized point biserial correlation coefficients for subjects with conversions, i.e., CN-MCI and MCI-AD, during a period
of 10 years from the baseline. Each panel represents the potential cell units for ‘model biomarkers,’ whose activations were highly
correlated with the conversions.
as follows: (i) ≈ 3 subjects (3.6 ± 2.3) showed transitions from CN to MCI (CN-MCI), (ii) ≈ 13 subjects
(13.4 ± 6.0) showed transitions from MCI to AD (MCI-AD), and (iii) ≈ 2 subjects (2.0 ± 1.6) showed
transitions through all the statuses of CN, MCI, and AD (CN-MCI-AD). Then, we analyzed the calculated
point-biserial correlations for CN-MCI and MCI-AD 7.
Regarding the variation of conversion time among subjects per group, we normalized the point-biserial
correlation coefficients with the standard deviation of the coefficients in each group. Then, we sorted the
normalized coefficients to identify the significant cell states related to the transitions, as presented in Fig.
E.3. From the sorted cells, we focused on cell units with the top 25% most extreme coefficients per group.
Of the selected cell units, the common ≈ 15 cell units (15.4 ± 1.1) in both groups are presented in Fig. 8,
where the subfigures correspond to one fold of our five-fold cross-validation experiments. As these cell states
showed high correlations either positively or negatively, we believe that those cell units could be potentially
used as ‘model biomarkers’ with respect to the clinical status conversion. Interestingly, across the five-fold
experiments, a similar number (14∼17) of cell units showed high correlation with the clinical status change.
7We excluded the CN-MCI-AD group for simplicity in interpretation.
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Figure 9: Examples of individual trajectories of MRI biomarkers are the amount of change over time. The color-coded values indicate
the normalized relative changes from the respective regions’ values at baseline. (GT: ground truth)
From this observation, we infer the robustness or generalizability of our method over different training sets.
5.6. Individual MRI Biomarker Value Changes over Time
In regard to the relationship between the MRI biomarker values and the clinical statuses over time, we
visualized the trajectories of the amount of MRI biomarker change and the corresponding clinical status in
Fig. 9. We computed the relative changes in the prediction (p) and the ground truth (g) from the respective
regions’ values to the baseline as follows:
r
(i)
g,t =
y
(i)
t − y(i)0
y
(i)
0
, r
(i)
p,t =
yˆ
(i)
t − y(i)0
y
(i)
0
where i and t denote the indices of MRI biomarkers and time points, respectively. Those relative changes
were then normalized with the minimum and maximum values such that the resulting values were in the
range of -1 to 1, in which the positive and negative values denote increasing and decreasing, respectively.
As a result, in comparisons between the predictions and the ground truths, they showed very similar values
over time and across cases. This again demonstrates that our proposed method was good at forecasting the
longitudinal MRI biomarkers. Second, unlike the two examples of Fig. 9a and Fig. 9b, which presents stable
or slowly deteriorating status over the period, when involving the progression to other statuses in the AD
spectrum (Fig. 9c and Fig. 9d), there were relatively rapid changes in values, i.e., enlarged ventricles and
shrunken other (sub)cortical regions.
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6. Conclusion
Progressive neurodegenerative AD is of great concern around the world due to its clinical, social, and
economic impacts. As there is no treatment or medicine to cure or reverse the progression of AD itself, many
researchers in various fields have been devoting their efforts to early diagnosis or prognosis in diverse ways.
In particular, the use of neuroimaging data is one of the main areas of study, as it provides quantitative and
qualitative measurements on which we can build computational models to predict the risk of AD progression.
Of various strategies for accurate AD diagnosis or prognosis, recent studies on longitudinal datasets val-
idated the significance of using historical observations. In that regard, we formulated the problem of AD
progression prognosis, i.e., the tasks of MRI biomarker forecasting and clinical status prediction over mul-
tiple time points, by means of the disease progression modeling. From a methodological standpoint, we
proposed a deep recurrent neural network that is jointly and systematically capable of imputing missing
observations, encoding historical inputs into hidden state vector representations, and predicting future MRI
biomarker values and the respective clinical status. We have performed exhaustive experiments and analyses
by comparing with other comparative methods in the literature. First, our proposed method was superior to
those competing methods in various quantitative metrics. Second, our method resulted in more stable (low-
bias and low-variance) outputs in MRI biomarker forecasting and more reasonable clinical status prediction
by reflecting the characteristics of irreversible AD (i.e., no status-reverse prediction was made over time).
Lastly, we observed that some internal state vector representations, i.e., the cell states in our LSTM, showed
high correlation with the clinical state-conversion, implying the potential use of those as ‘model biomarkers’
in predicting clinical status conversion in the near future.
As we considered only the six MRI biomarkers in this work, our forthcoming research direction will
be to accommodate the MRI biomarkers of the whole brain and to integrate functional and/or genotypic
information in multi-modal learning. Further, in order to get new insights about the AD progression, it is also
important to adopt interpretable and explainable mechanisms in the model.
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Appendix A. Summary of the TADPOLE dataset
Table A.1: Demographic information of subjects in the TADPOLE dataset. Values are reported as a mean ± standard deviation. Note
that the number of subjects is measured at the baseline time point and includes missing observation values and clinical statuses during
the subject’s visits.
Clinical Status
# of subjects # of visits Age (mean± std.)
Male Female Male Female Male Female
Cognitively Normal (CN) 253 270 2, 126 2, 084 75.10± 5.64 74.42± 5.38
Mild Cognitive Impairment (MCI) 515 357 4, 207 2, 756 73.71± 7.11 71.80± 7.85
Alzheimer’s Disease (AD) 189 153 884 684 75.56± 7.11 74.52± 7.81
All 1, 737 12, 741 73.81± 6.97
Appendix B. Anatomical regions of the 6 MRI Biomarkers
Figure B.1: Visualization of six MRI volumetric biomarkers that are used in our experiments. This figure was generated by the Brain-
Painter (Marinescu et al., 2019).
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Appendix C. Statistics of the Demographic and Clinical Scores
Table C.2: Statistical information on a demographic and clinical score for each group every year. Scores on the CDR-SOB, ADAS-cog11,
and ADAS-cog13 were higher at severe levels of cognitive dysfunction. Conversely, scores on the MMSE were lower at serious levels
of cognitive dysfunction.
Year Groups Number (Gender) Age MMSE ADAS-cog11 ADAS-cog13 CDR-SOB
Baseline
CN 271 (M/F: 137/134) 74.7±5.5 29.1±1.1 5.9±2.8 9.1±4.2 0.0±0.1
MCI 483 (M/F: 289/194) 72.1±7.4 27.7±1.8 9.8±4.4 15.8±6.6 1.5±0.9
AD 19 (M/F: 9/10) 74.8±6.6 22.7±1.9 20.1±5.8 30.9±7.1 4.0±1.4
1
CN 282 (M/F: 139/143) 74.1±5.9 29.1±1.2 5.2±2.8 8.1±4.3 0.1±0.3
MCI 413 (M/F: 249/164) 72.5±7.4 27.7±2.1 9.4±4.9 15.0±7.2 1.6±1.2
AD 73 (M/F: 44/29) 72.5±7.0 22.8±4.0 18.7±7.0 29.0±8.6 4.3±1.8
2
CN 275 (M/F: 143/132) 74.1±5.9 29.2±1.1 5.3±3.1 8.4±4.6 0.1±0.4
MCI 336 (M/F: 194/142) 72.4±7.5 27.8±2.0 9.1±4.6 14.7±7.1 1.5±1.0
AD 136 (M/F: 84/52) 72.9±7.0 22.3±4.3 19.7±8.6 29.6±9.7 5.3±2.3
3
CN 191 (M/F: 95/96) 73.8±6.1 29.1±1.2 5.0±2.5 8.1±4.0 0.2±0.4
MCI 296 (M/F: 177/119) 72.3±7.5 27.8±2.1 9.0±4.9 14.4±7.3 1.5±1.2
AD 153 (M/F: 87/66) 73.2±6.8 21.2±5.4 22.1±10.6 31.8±11.1 6.2±3.2
4
CN 187 (M/F: 93/94) 73.2±6.3 29.1±1.2 5.6±2.9 8.6±4.5 0.1±0.4
MCI 202 (M/F: 123/79) 72.0±7.2 28.0±1.9 8.3±4.0 13.5±6.2 1.4±1.1
AD 110 (M/F: 65/45) 72.1±6.8 20.6±5.3 22.9±11.7 33.6±13.6 6.5±3.1
5
CN 93 (M/F: 45/48) 74.1±5.9 29.2±1.2 5.6±3.3 8.8±4.7 0.1±0.3
MCI 111 (M/F: 70/41) 72.0±7.0 27.5±2.1 8.9±4.1 14.4±6.6 1.6±1.2
AD 61 (M/F: 34/27) 72.1±6.7 20.1±5.8 26.2±13.2 37.5±15.6 7.2±3.4
6
CN 83 (M/F: 42/41) 74.5±4.8 28.9±1.5 5.7±2.9 9.0±4.4 0.2±0.3
MCI 61 (M/F: 42/19) 73.9±6.8 27.7±2.1 9.6±4.9 15.3±7.2 1.6±1.5
AD 49 (M/F: 28/21) 73.1±6.7 18.5±6.2 27.4±14.7 38.9±16.6 8.1±3.8
7
CN 61 (M/F: 32/29) 74.8±4.2 29.1±1.2 5.0±2.8 8.2±4.0 0.2±0.4
MCI 59 (M/F: 37/22) 74.4±6.2 27.8±1.9 9.6±4.3 15.6±6.9 1.4±1.0
AD 34 (M/F: 18/16) 72.1±6.4 18.7±5.6 27.5±12.1 39.5±13.5 8.7±3.6
8
CN 43 (M/F: 23/20) 75.3±4.6 28.8±1.3 5.7±2.8 9.4±4.2 0.2±0.4
MCI 40 (M/F: 26/14) 74.1±6.4 27.6±2.3 10.4±4.9 16.5±6.9 1.5±1.1
AD 30 (M/F: 18/12) 73.5±6.9 19.2±6.4 25.6±12.1 37.3±14.5 7.3±3.7
9
CN 26 (M/F: 14/12) 73.8±3.5 29.2±1.3 5.3±2.4 8.1±3.7 0.1±0.3
MCI 29 (M/F: 17/12) 73.3±5.9 27.9±2.4 9.3±3.8 14.9±5.9 1.3±1.2
AD 27 (M/F: 15/12) 74.7±5.9 19.4±4.8 22.6±8.0 33.9±10.0 6.8±4.3
10
CN 20 (M/F: 10/10) 74.9±4.8 28.9±1.0 5.5±2.9 9.6±4.5 0.1±0.2
MCI 20 (M/F: 14/6) 76.0±5.8 27.2±2.1 11.2±5.3 17.6±7.9 1.8±1.5
AD 14 (M/F: 7/7) 73.5±4.9 21.4±6.1 23.1±11.6 33.9±14.0 6.9±2.7
? Age, MMSE, CDR-SB, ADAS-cog11, and ADAS-cog13 are listed as (Mean± Standard deviation).
? Abbreviation: AD, Alzheimer’s disease; ADAS-cog, Alzheimer’s Disease Assessment Scale-cognitive subscale; CDR-SOB,
Clinical Dementia Rating scale-Sum of the Boxes; CN, Cognitively Normal; F, Female; M, Male; MCI, Mild Cognitive Impair-
ment; MMSE, Mini-Mental State Examination.
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Appendix D. Performance across Time
We took the average of the metrics, i.e., mAUC, precision, and recall, from all time sequences, with a
result of mAUC = 0.7718, precision = 0.4821, and recall = 0.5361.
Table D.3: Longitudinal regression results for each year in each of the specific volumes for the brain. We observed that the data imbalance
was caused over time but the performance did not changed significantly. Additionally, the value of MAE decreased and the accuracy of
classification increased over time.
Year 1 2 3 4 5 6 7 8 9 10
# of subjects
CN 141 134 91 92 49 42 29 23 14 10
MCI 203 167 146 103 56 26 27 17 10 6
AD 41 76 87 58 26 25 16 14 16 6
MRI Biomarker Regression (MAE)
Ventricles 2.616 2.533 2.549 2.102 1.787 1.969 1.884 2.512 2.557 1.643
Hippocampus 0.182 0.168 0.163 0.166 0.175 0.191 0.181 0.208 0.221 0.081
Whole Brain 11.905 11.379 10.436 14.339 16.579 17.909 17.073 18.828 7.559 10.410
Entorhinal Cortex 0.205 0.196 0.158 0.267 0.233 0.204 0.271 0.143 0.390 0.036
Fusiform Gyrus 0.438 0.452 0.353 0.561 0.558 0.590 0.545 0.426 0.558 0.600
Middle Temporal Gyrus 0.486 0.498 0.551 0.608 0.610 0.691 0.815 0.368 0.401 0.066
AD vs. MCI vs. CN
mAUC 0.716 0.756 0.794 0.778 0.786 0.760 0.786 0.757 0.761 0.824
Precision 0.553 0.492 0.572 0.471 0.547 0.286 0.529 0.438 0.333 0.600
Recall 0.695 0.701 0.678 0.709 0.625 0.308 0.333 0.412 0.400 0.500
Figure D.2: Yearly computed multi-class classification confusion matrices with normalization using our proposed method. The diagonal
elements are the number of points where the predicted labels were the same as the real labels, excluding missing labels, whereas the
non-diagonal elements were misclassified by our proposed method. The higher the diagonal value and the darker the shade of blue, the
more accurate is the diagnosis of the clinical status.
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Appendix E. Interpreting Cell States
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(b) MCI-AD
Figure E.3: Normalized point biserial correlation coefficients for subjects with conversion from CN to MCI (left) and from MCI to AD
(right) during a period of 10 years from the baseline.
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